Medroxyprogesterone acetate exacerbates glutamate excitotoxicity

References

• Brinton R D. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem 2001; 8: 121–133
   PubMed Web of Science ®Google Scholar
• McEwen B S. The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab 1999; 84: 1790–1797
   PubMed Web of Science ®Google Scholar
• Green P S, Simpkins J W. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000; 18: 347–358
   PubMed Web of Science ®Google Scholar
• Wise P M, Dubal D B, Wilson M E, Rau S W, Bottner M, Rosewell K L. Estradiol is a protective factor in the adult and aging brain: understanding of mechanisms derived from in vivo and in vitro studies. Brain Res Brain Res Rev 2001; 37: 313–319
   PubMed Web of Science ®Google Scholar
• Hurn P D, Brass L M. Estrogen and stroke: a balanced analysis. Stroke 2003; 34: 338–341
   PubMed Web of Science ®Google Scholar
• Resnick S M, Maki P M, Golski S, Kraut M A, Zonderman A B. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 1998; 34: 171–182
   PubMed Web of Science ®Google Scholar
• Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J Am Med Assoc 1998; 279(9)688–695
   PubMed Web of Science ®Google Scholar
• Zandi P P, Carlson M C, Plassman B L, Welsh-Bohmer K A, Mayer L S, Steffens D C, Breitner J C. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. J Am Med Assoc 2002; 288: 2123–2129
   PubMed Web of Science ®Google Scholar
• Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, Zabriskie J. Observations in a preliminary open trial of estradiol therapy for senile dementia–Alzheimer's type. Psychoneuroendocrinology 1986; 11: 337–345
   PubMed Web of Science ®Google Scholar
• Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle D D, Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517–1521
   PubMed Web of Science ®Google Scholar
• Singer C A, Rogers K L, Strickland T M, Dorsa D M. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett 1996; 212: 13–16
   PubMedGoogle Scholar
• Nilsen J, Brinton R D. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002; 143: 205–212
   PubMed Web of Science ®Google Scholar
• Vongher J M, Frye C A. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol Biochem Behav 1999; 64: 777–785
   PubMed Web of Science ®Google Scholar
• Roof R L, Duvdevani R, Stein D G. Gender influences outcome of brain injury: progesterone plays a protective role. Brain Res 1993; 607: 333–336
   PubMed Web of Science ®Google Scholar
• Nilsen J, Brinton R D. Impact of progestins on estradiol potentiation of the glutamate calcium response. Neuroreport 2002; 13: 825–830
   PubMedGoogle Scholar
• Brinton R D. Estrogen induction of rapid changes in the growth of cultured hippocampal nerve cells. Mol Cell Neurosci 1993; 4: 36–46
   PubMed Web of Science ®Google Scholar
• Koh J Y, Choi D W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 1987; 20: 83–90
   PubMed Web of Science ®Google Scholar
• O'Neill K, Chen S, Brinton R D. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 2004; 185: 63–80
   PubMed Web of Science ®Google Scholar
• Mattson M P, Kater S B. Excitatory and inhibitory neurotransmitters in the generation and degeneration of hippocampal neuroarchitecture. Brain Res 1989; 478: 337–348
   PubMed Web of Science ®Google Scholar
• Mattson M P. Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol 1992; 27: 29–49
   PubMed Web of Science ®Google Scholar
• Nilsen J, Brinton R D. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 2003; 100: 10506–10511
   PubMed Web of Science ®Google Scholar
• Littleton-Kearney M T, Klaus J A, Hurn P D. Effects of combined oral conjugated estrogens and medroxyprogesterone acetate on brain infarction size after experimental stroke in rat. J Cereb Blood Flow Metab 2005; 25: 421–426
   PubMed Web of Science ®Google Scholar
• Murphy S J, Littleton-Kearney M T, Hurn P D. Progesterone administration during reperfusion, but not preischemia alone, reduces injury in ovariectomized rats. J Cereb Blood Flow Metab 2002; 22: 1181–1188
   PubMedGoogle Scholar
• Payami H, Montee K, Grimslid H, Shattuc S, Kaye J. Increased risk of familial late-onset Alzheimer's disease in women. Neurology 1996; 46: 126–129
   PubMedGoogle Scholar
• Henderson V W, Buckwalter J G. Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994; 44: 90–96
   PubMed Web of Science ®Google Scholar
• Wenger N K, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247–256
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc 1995; 273: 199–208
   PubMed Web of Science ®Google Scholar
• Marchbanks P A, McDonald J A, Wilson H G, Folger S G, Mandel M G, Daling J R, Bernstein L, Malone K E, Ursin G, Strom B L, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025–2032
   PubMed Web of Science ®Google Scholar
• Falkeborn M, Persson I, Adami H O, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen–progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821–828
   PubMedGoogle Scholar
• Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324–327
   PubMed Web of Science ®Google Scholar